Shionogi (4507) Stock Overview
Researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 4507 from our risk checks.
4507 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Shionogi & Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,572.00 |
| 52 Week High | JP¥2,724.00 |
| 52 Week Low | JP¥2,028.50 |
| Beta | 0.12 |
| 1 Month Change | 2.47% |
| 3 Month Change | 6.81% |
| 1 Year Change | 13.97% |
| 3 Year Change | 15.34% |
| 5 Year Change | 31.14% |
| Change since IPO | 718.24% |
Recent News & Updates
Shionogi & Co., Ltd. Just Recorded A 8.7% EPS Beat: Here's What Analysts Are Forecasting Next
Jul 30
Shionogi & Co., Ltd.'s (TSE:4507) Business Is Yet to Catch Up With Its Share Price
Jul 21Recent updates
Shionogi & Co., Ltd. Just Recorded A 8.7% EPS Beat: Here's What Analysts Are Forecasting Next
Jul 30Shionogi & Co., Ltd.'s (TSE:4507) Business Is Yet to Catch Up With Its Share Price
Jul 21Analysts Are Updating Their Shionogi & Co., Ltd. (TSE:4507) Estimates After Its Full-Year Results
May 14There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price
Mar 23Is There An Opportunity With Shionogi & Co., Ltd.'s (TSE:4507) 50% Undervaluation?
Mar 01We Think Shionogi's (TSE:4507) Healthy Earnings Might Be Conservative
Feb 07Shionogi & Co., Ltd. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 04There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price
Nov 26Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 30Shionogi's (TSE:4507) Dividend Will Be ¥85.00
Sep 11Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00
Aug 28Shareholder Returns
| 4507 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.0% | -3.9% | -0.9% |
| 1Y | 14.0% | -15.6% | 13.6% |
Return vs Industry: 4507 exceeded the JP Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: 4507 matched the JP Market which returned 13.6% over the past year.
Price Volatility
| 4507 volatility | |
|---|---|
| 4507 Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 1.7% |
Stable Share Price: 4507 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4507's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1878 | 4,955 | Isao Teshirogi | www.shionogi.com |
Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases. The company was formerly known as Shionogi Shoten Co., Ltd.
Shionogi & Co., Ltd. Fundamentals Summary
| 4507 fundamental statistics | |
|---|---|
| Market cap | JP¥2.17t |
| Earnings (TTM) | JP¥179.12b |
| Revenue (TTM) | JP¥440.50b |
Is 4507 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4507 income statement (TTM) | |
|---|---|
| Revenue | JP¥440.50b |
| Cost of Revenue | JP¥61.68b |
| Gross Profit | JP¥378.82b |
| Other Expenses | JP¥199.70b |
| Earnings | JP¥179.12b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 27, 2025
| Earnings per share (EPS) | 210.48 |
| Gross Margin | 86.00% |
| Net Profit Margin | 40.66% |
| Debt/Equity Ratio | 0% |
How did 4507 perform over the long term?
See historical performance and comparisonDividends
Does 4507 pay a reliable dividends?
See 4507 dividend history and benchmarks| Shionogi dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2025 |
| Dividend Pay Date | Dec 02 2025 |
| Days until Ex dividend | 31 days |
| Days until Dividend pay date | 95 days |
Does 4507 pay a reliable dividends?
See 4507 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 16:07 |
| End of Day Share Price | 2025/08/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shionogi & Co., Ltd. is covered by 24 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |